Aggressive Inferior Eyelid Basal Cell Carcinoma: Advantage of Neoadjuvant Vismodegib.

Monteiro, A F

Aggressive Inferior Eyelid Basal Cell Carcinoma: Advantage of Neoadjuvant Vismodegib. [electronic resource] - Actas dermo-sifiliograficas Dec 2019 - 863-865 p. digital

Publication Type: Case Reports; Letter

2173-5778

10.1016/j.ad.2018.05.022 doi


Aged, 80 and over
Anilides--therapeutic use
Carcinoma, Basal Cell--drug therapy
Eyelid Neoplasms--drug therapy
Humans
Male
Neoadjuvant Therapy
Pyridines--therapeutic use